UK-based synthetic promoter and gene control company Synpromics and GE Healthcare are set to collaborate to develop customised synthetic promoters.
These promoters will be optimised for GE Healthcare’s biopharmaceutical manufacturing platform.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As part of the research partnership, Synpromics will use its PromPT platform to develop a complex bar-coded library of synthetic promoters for screening in GE Healthcare’s Chinese Hamster Ovary (CHO) based expression system.
The characterised promoter toolbox is a result of this collaboration and is expected to have broad applicability for increasing the yield of various biopharmaceuticals, including proteins that are difficult to manufacture.
Synpromics CEO Dr David Venables said: “We are delighted to be working with GE Healthcare, a world leading technology innovator to develop and commercialise our novel synthetic promoter platform.
“We believe our synthetic promoters will provide a much more efficient production system and we’re aiming to help GE Healthcare boost efficiency for its biopharma customers.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataUnder the collaboration, GE Healthcare will pay an upfront technology access fee and would also obtain rights to commercialise the improved platform.
GE Healthcare life sciences business upstream and cell culture general manager Morgan Norris said: “We are happy to be able to collaborate with Synpromics on developing enhanced tools for manufacturing biologics and thereby support our customers in their production efforts.”
Synpromics has partnership deals with various gene therapy companies, including AGTC, Adverum, and uniQure.
